In myxoid liposarcoma with the FUS-CHOP fusion gene, the pharmacological mechanism of trabectedin is to block the trans-activating chimera, resulting in the detachment of the FUS-CHOP chimera from targeted promoters [99]. This evidence concerns the gene DDIT3 and myxoid liposarcoma.